Claudia Niccolai
University of Florence
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claudia Niccolai.
Multiple Sclerosis Journal | 2014
Maria Pia Amato; Benedetta Goretti; Rosa Gemma Viterbo; Emilio Portaccio; Claudia Niccolai; Bahia Hakiki; Pietro Iaffaldano; Maria Trojano
Background: There is controversial information on the efficacy of cognitive rehabilitation in multiple sclerosis (MS). Objective: The objective of this paper is to test a home-based computerized program for retraining attention dysfunction in MS. Methods: Relapsing–remitting patients who failed > 2 tests of attention on an extensive neuropsychological battery were randomized to specific or nonspecific computerized training (ST, n-ST), in one-hour sessions, twice a week for three months. Outcome measures included neuropsychological assessment, depression, fatigue, everyday activities and a visual analogue scale assessing attentive performance (VAS). Assessments were repeated after the interventions and after a further three months. Statistical analysis included the analysis of variance (ANOVA) for repeated measures. Results: Eighty-eight out of 102 randomized patients completed the study (69 women, age 40.9 ± 11.5 years, disease duration 13.0 ± 8.7 years, Expanded Disability Status Scale score 2.7 ± 1.5). Fifty-five patients were randomized to ST, 33 to n-ST. A benefit of the ST was observed on the Paced Auditory Serial Addition Test (p < 0.002). However, patient self-report did not reveal differences between ST and n-ST patient groups. Conclusion: Although our program trained different attention components, we could detect some improvements exclusively on tasks of sustained attention. Moreover, patient self-perceived results may be independent of the training program.
BMC Neurology | 2014
Benedetta Goretti; Claudia Niccolai; Bahia Hakiki; Andrea Sturchio; Monica Falautano; Eleonora Minacapelli; Vittorio Martinelli; Chiara Incerti; Ugo Nocentini; Monica Murgia; Giuseppe Fenu; Eleonora Cocco; Maria Giovanna Marrosu; Elisabetta Garofalo; Ferdinando Ivano Ambra; Maurizio Maddestra; Marilena Consalvo; Rosa Gemma Viterbo; Maria Trojano; Nunzia Alessandra Losignore; Giovanni Bosco Zimatore; Erika Pietrolongo; Alessandra Lugaresi; Dawn Langdon; Emilio Portaccio; Maria Pia Amato
BackgroundBICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) has been recently developed as brief, practical and universal assessment tool for cognitive impairment in MS subjects. It includes the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) . In this study we aimed at gathering regression based normative data for the BICAMS battery in the Italian population.MethodsHealthy subjects were consecutively recruited among patient friends and relatives. Corrections for demographics were calculated using multivariable linear regression models. Test-retest reliability was assessed using the Pearson correlation coefficient.ResultsThe BICAMS battery was administered to 273 healthy subjects (180 women, mean age 38.9 ± 13.0 years, mean education 14.9 ± 3.0 years). Test-retest reliability was good for all the tests.ConclusionsThe study provided normative data of the BICAMS for the Italian population confirming good test-retest reliability which can facilitate the use of the battery in clinical practice, also for longitudinal patient assessments.
Neurology | 2014
Maria Pia Amato; Benedetta Goretti; A. Ghezzi; Bahia Hakiki; Claudia Niccolai; S. Lori; Lucia Moiola; Monica Falautano; Rosa Gemma Viterbo; Francesco Patti; Sabina Cilia; Carlo Pozzilli; Valentina Bianchi; Marco Roscio; Vittorio Martinelli; Giancarlo Comi; Emilio Portaccio; Maria Trojano
Objective: The aim of the study was to perform a third cognitive assessment in our pediatric-onset multiple sclerosis (MS) patient cohort and determine predictors of the individual cognitive outcome. Methods: After 4.7 ± 0.7 years from baseline evaluation, 48 of 63 patients in the original cohort were reassessed on an extensive neuropsychological battery and compared with 46 healthy controls. Two alternate versions of the tests were used at different assessment points. Cognitive impairment was defined as the failure of ≥3 tests; individual change in the cognitive impairment index was measured. Results: At year 5, 38% of the subjects with MS fulfilled our criterion for impairment. Between years 2 and 5, regarding individual cognitive impairment index change, 66.7% of the patients improved. However, comparing baseline and 5-year testing (when the same versions of the tests were used), cognitive impairment index deterioration was observed in 56% of the patients, improvement in 25%, and stability in 18.8%. A deteriorating performance was related to male sex, younger age and age at MS onset, and lower education. None of these variables, however, was retained in the multivariate analysis. Conclusions: Cognitive outcome in pediatric-onset MS can be heterogeneous. Progression of cognitive problems in a few subjects and potential for compensation and improvement in others call for systematic cognitive screening in this population and development of effective treatment strategies.
Multiple Sclerosis Journal | 2017
Luis Ruano; Emilio Portaccio; Benedetta Goretti; Claudia Niccolai; Milton Severo; Francesco Patti; Sabina Cilia; Paolo Gallo; Paola Grossi; A. Ghezzi; Marco Roscio; Flavia Mattioli; Chiara Stampatori; Maria Trojano; Rosa Gemma Viterbo; Maria Pia Amato
Background: There is limited and inconsistent information on the clinical determinants of cognitive impairment (CI) in multiple sclerosis (MS). Objective: The aim of this study was to compare the prevalence and profile of CI across MS disease subtypes and assess its clinical determinants. Methods: Cognitive performance was assessed through the Brief Repeatable Battery and the Stroop test in consecutive patients with MS referred to six Italian centers. CI was defined as impairment in ⩾ 2 cognitive domains. Results: A total of 1040 patients were included, 167 with clinically isolated syndrome (CIS), 759 with relapsing remitting (RR), 74 with secondary progressive (SP), and 40 with primary progressive (PP) disease course. The overall prevalence of CI was 46.3%; 34.5% in CIS, 44.5% in RR, 79.4% in SP, and 91.3% in PP. The severity of impairment and the number of involved domains were significantly higher in SP and primary progressive multiple sclerosis (PPMS) than in CIS and RR. In multivariable logistic regression analysis, the presence of CI was significantly associated with higher Expanded Disability Status Scale (EDSS) and older age. Conclusion: CI is present in all MS subtypes since the clinical onset and its frequency is increased in the progressive forms, but these differences seem to be more associated with patient age and physical disability than to disease subtype per se.
Multiple Sclerosis Journal | 2016
Luisa Pastò; Emilio Portaccio; Benedetta Goretti; A. Ghezzi; S. Lori; Bahia Hakiki; Marta Giannini; Isabella Righini; Lorenzo Razzolini; Claudia Niccolai; Lucia Moiola; Monica Falautano; Marta Simone; Rosa Gemma Viterbo; Francesco Patti; Sabina Cilia; Carlo Pozzilli; Valentina Bianchi; Marco Roscio; Vittorio Martinelli; Giancarlo Comi; Maria Trojano; Maria Pia Amato
Background: The study of cognitive reserve (CR) in relationship with cognitive impairment (CI) in pediatric-onset multiple sclerosis (POMS) may provide cues to identifying subjects at higher risk of impairment and scope for therapeutic strategies. Objectives: To assess the potential impact of CR on cognition in a cohort of POMS patients. Methods: In all, 48 POMS patients were followed up for 4.7 ± 0.4 years. CI was defined as the failure of ⩾3 tests on an extensive neuropsychological battery. Change of neuropsychological performance was assessed through the Reliable Change Index (RCI) method. At baseline, CR was estimated by measuring the intelligence quotient (IQ). The relationships were assessed through multivariable regression analyses. Results: At baseline, CI was detected in 14/48 (29.2%) patients. Two out of 57 healthy control (HC; 3.5%) met the same criteria of CI (p < 0.001). A deteriorating cognitive performance using the RCI method was observed in 18/48 patients (37.6%). Among the 34 cases who were cognitively preserved at baseline, a higher reserve predicted stable/improving performance (odds ratio (OR) = 1.11; 95% confidence interval (CI): 1.03–1.20; p = 0.006). Conclusion: Our results suggest that higher CR in POMS patients may protect from CI, particularly in subjects with initial cognitive preservation, providing relevant implications for counseling and rehabilitation strategies.
Multiple Sclerosis Journal | 2018
Luis Ruano; Mariana Branco; Emilio Portaccio; Benedetta Goretti; Claudia Niccolai; Francesco Patti; Clara Chisari; Paolo Gallo; Paola Grossi; A. Ghezzi; Marco Roscio; Flavia Mattioli; Chiara Stampatori; Marta Simone; Rosa Gemma Viterbo; Maria Pia Amato
Background: Patients with paediatric-onset multiple sclerosis (POMS) could be at an increased risk for cognitive impairment (CI), given the potential harmful effects of disease activity in neurodevelopment. However, there is scarce information on their long-term cognitive outcomes. Objective: To compare the prevalence and profile of CI between adults with a history of POMS and those with classic, adult-onset multiple sclerosis (AOMS). Methods: Cognitive performance was assessed through the Brief Repeatable Battery (BRB) and the Stroop Test in consecutive patients referred to six Italian MS centres. CI was defined as impairment in ⩾2 cognitive domains. Results: In all, 119 patients with POMS and 712 with AOMS were included in this analysis. The prevalence of CI was 48.0% in AOMS, 44.5% in POMS; with similar neuropsychological profile between the two groups. However, when adjusting for current age, we found a significantly increased risk for CI (odds ratio (OR) = 1.71; p = 0.02) and for impairment in information processing speed (OR = 1.86; p < 0.01) in patients with POMS. A higher Expanded Disability Status Scale (EDSS) was also identified in POMS (p = 0.03) compared with AOMS patients. Conclusion: Patients with a history of POMS appear to be at higher risk of physical and cognitive disability than AOMS patients, after correcting for age effects, with particular involvement of information processing speed.
Multiple Sclerosis and Demyelinating Disorders | 2017
Claudia Niccolai; Benedetta Goretti; Maria Pia Amato
Cognitive dysfunction is frequent in multiple sclerosis patients and has important and negative consequences for daily activities and quality of life of subjects. Disease modifying treatments for multiple sclerosis reduce the incidence of relapses and may prevent disease progression, but the influence on cognitive impairment is unclear, due to several limitations of the available studies. Moreover, symptomatic drugs for the improvement of already established cognitive deficits have been tested in small pilot studies, providing conflicting or mainly negative results. Currently, specific pharmacological therapies for the management of cognitive deficits in MS have not yet been developed. We will provide an updated overview of available evidence of pharmacological approaches for ameliorating cognitive deficits, based either on disease modifying treatments or symptomatic drugs.
Developmental Neuropsychology | 2017
Nadine Akbar; Alessio Signori; Maria Pia Amato; Maria Pia Sormani; Emilio Portaccio; Claudia Niccolai; Benedetta Goretti; Christine Till; Brenda Banwell
ABSTRACT Processing speed is a frequently affected cognitive domain in pediatric multiple sclerosis (MS) and is commonly assessed using the Symbol Digit Modalities Test (SDMT). The objective of this study was to determine maturational trajectories in SDMT performance and baseline factors affecting trajectories in a sample of 82 pediatric MS individuals. Performance on the SDMT increased with age in patients with pediatric MS followed by a subsequent decline. Furthermore, patients who were older at disease onset and had a higher IQ showed greater gains with age, suggesting that these factors may be protective with respect to cognitive maturation in pediatric MS.
Neurological Sciences | 2014
Benedetta Goretti; Rosa Gemma Viterbo; Emilio Portaccio; Claudia Niccolai; Bahia Hakiki; Elisa Piscolla; Pietro Iaffaldano; Maria Trojano; Maria Pia Amato
BMC Neurology | 2015
Claudia Niccolai; Emilio Portaccio; Benedetta Goretti; Bahia Hakiki; Marta Giannini; Luisa Pastò; Isabella Righini; Monica Falautano; Eleonora Minacapelli; Vittorio Martinelli; Chiara Incerti; Ugo Nocentini; Giuseppe Fenu; Eleonora Cocco; Maria Giovanna Marrosu; Elisa Garofalo; Ferdinando Ivano Ambra; Maurizio Maddestra; Marilena Consalvo; Rosa Gemma Viterbo; Maria Trojano; Nunzia Alessandra Losignore; Giovanni Bosco Zimatore; Erika Pietrolongo; Alessandra Lugaresi; Lorena Pippolo; Marco Roscio; A. Ghezzi; Debora Castellano; Sergio Stecchi